Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CKPT Checkpoint Therapeutics	$4.12	$3.81	$1.47 ▼ $4.50	$345.11M	1.18	1.25 million shs	1.26 million shs
DYN Dyne Therapeutics	$11.86 -1.1%	$10.58	$6.36 ▼ $47.45	$1.35B	1.21	1.56 million shs	1.04 million shs
GPCR Structure Therapeutics	$27.09 -0.9%	$20.52	$13.22 ▼ $62.74	$1.55B	-1.35	922,943 shs	739,761 shs
OCUL Ocular Therapeutix	$8.80 +3.2%	$7.40	$4.79 ▼ $11.78	$1.40B	1.51	1.44 million shs	1.56 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CKPT Checkpoint Therapeutics	0.00%	+0.49%	+1.98%	+45.07%	+194.29%
DYN Dyne Therapeutics	-1.08%	+7.23%	+19.68%	-16.60%	-54.08%
GPCR Structure Therapeutics	-0.88%	+14.11%	+59.82%	-9.61%	-31.10%
OCUL Ocular Therapeutix	+3.17%	+14.14%	+19.89%	+14.29%	+75.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CKPT Checkpoint Therapeutics	2.3398 of 5 stars	1.2	4.0	4.2	2.1	0.8	0.0
DYN Dyne Therapeutics	3.3894 of 5 stars	4.5	1.0	0.0	3.3	4.2	0.0
GPCR Structure Therapeutics	2.4332 of 5 stars	3.5	1.0	0.0	3.9	1.7	0.6
OCUL Ocular Therapeutix	3.6286 of 5 stars	3.4	1.0	4.1	3.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CKPT Checkpoint Therapeutics	2.33	Hold	$4.33	5.18% Upside
DYN Dyne Therapeutics	3.07	Buy	$47.46	300.18% Upside
GPCR Structure Therapeutics	3.00	Buy	$78.63	190.24% Upside
OCUL Ocular Therapeutix	2.89	Moderate Buy	$16.38	86.08% Upside

Current Analyst Ratings Breakdown

Latest CKPT, GPCR, OCUL, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/2/2025	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
4/22/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/8/2025	OCUL Ocular Therapeutix	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/8/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/31/2025	CKPT Checkpoint Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.80 ➝ $4.80
3/21/2025	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$18.00 ➝ $17.00
3/18/2025	OCUL Ocular Therapeutix	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$17.00
3/17/2025	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
3/17/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
3/12/2025	DYN Dyne Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
3/11/2025	CKPT Checkpoint Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$4.10

(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CKPT Checkpoint Therapeutics	$41K	8,417.26	N/A	N/A	($0.47) per share	-8.77
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$1.49 per share	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$9.77 per share	N/A
OCUL Ocular Therapeutix	$63.72M	22.00	N/A	N/A	$0.79 per share	11.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CKPT Checkpoint Therapeutics	-$51.85M	-$1.43	N/A	∞	N/A	N/A	N/A	-659.07%	5/9/2025 (Estimated)
DYN Dyne Therapeutics	-$235.94M	-$3.35	N/A	N/A	N/A	N/A	-57.46%	-51.62%	N/A
GPCR Structure Therapeutics	-$89.62M	-$0.79	N/A	N/A	N/A	N/A	-16.37%	-15.68%	5/8/2025 (Estimated)
OCUL Ocular Therapeutix	-$80.74M	-$1.26	N/A	N/A	N/A	-283.74%	-45.18%	-30.87%	5/5/2025 (Estimated)

Latest CKPT, GPCR, OCUL, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	CKPT Checkpoint Therapeutics	-$0.10	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	N/A	N/A	N/A	N/A	N/A
5/5/2025	Q1 2025	OCUL Ocular Therapeutix	-$0.28	N/A	N/A	N/A	$17.02 million	N/A
3/28/2025	Q4 2024	CKPT Checkpoint Therapeutics	-$0.22	-$0.69	-$0.47	-$0.69	N/A	$0.04 million
3/4/2025	Q4 2024	DYN Dyne Therapeutics	-$0.92	-$0.88	+$0.04	-$0.88	N/A	N/A
3/3/2025	Q4 2024	OCUL Ocular Therapeutix	-$0.24	-$0.29	-$0.05	-$0.29	$16.89 million	$17.08 million
2/27/2025	Q4 2024	GPCR Structure Therapeutics	-$0.23	-$0.22	+$0.01	-$0.22	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CKPT Checkpoint Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CKPT Checkpoint Therapeutics	N/A	0.29	0.29
DYN Dyne Therapeutics	N/A	17.02	17.02
GPCR Structure Therapeutics	N/A	27.63	27.63
OCUL Ocular Therapeutix	0.19	13.01	12.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CKPT Checkpoint Therapeutics	22.00%
DYN Dyne Therapeutics	96.68%
GPCR Structure Therapeutics	91.78%
OCUL Ocular Therapeutix	59.21%

Insider Ownership

Company	Insider Ownership
CKPT Checkpoint Therapeutics	2.10%
DYN Dyne Therapeutics	20.77%
GPCR Structure Therapeutics	9.43%
OCUL Ocular Therapeutix	3.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CKPT Checkpoint Therapeutics	10	83.76 million	47.81 million	Optionable
DYN Dyne Therapeutics	100	113.63 million	80.63 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.86 million	Optionable
OCUL Ocular Therapeutix	230	159.29 million	151.71 million	Optionable

CKPT, GPCR, OCUL, and DYN Headlines

Recent News About These Companies

Ocular Therapeutix Inc (OCUL) Q1 2025: Everything You Need To Know Ahead Of Earnings

May 3 at 5:56 PM | finance.yahoo.com

Ocular Therapeutix (OCUL) Projected to Post Quarterly Earnings on Monday

May 3 at 2:22 AM | americanbankingnews.com

Ocular Therapeutix Q1 2025 Earnings Preview

May 2 at 2:42 PM | msn.com

Barclays PLC Reduces Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 2 at 3:43 AM | marketbeat.com

Ocular Therapeutix (OCUL) Projected to Post Quarterly Earnings on Tuesday

May 1 at 6:59 AM | marketbeat.com

Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

April 30 at 4:57 PM | seekingalpha.com

Ocular Therapeutix (NASDAQ:OCUL) Trading Up 5.4% - What's Next?

April 30 at 1:34 PM | marketbeat.com

Nantahala Capital Management LLC Sells 262,272 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

April 30 at 8:15 AM | marketbeat.com

Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences

April 29, 2025 | tmcnet.com

Analysts Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) Target Price at $16.38

April 29, 2025 | americanbankingnews.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Adage Capital Partners GP L.L.C.

April 28, 2025 | marketbeat.com

JPMorgan Chase & Co. Has $1.62 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

April 28, 2025 | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Recommendation of "Moderate Buy" by Brokerages

April 28, 2025 | marketbeat.com

Invesco Ltd. Acquires 134,573 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

April 27, 2025 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 5.8% - Should You Buy?

April 23, 2025 | marketbeat.com

Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Up 6.02%

April 21, 2025 | aaii.com

Geode Capital Management LLC Has $27.64 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

April 20, 2025 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Shares Down 4.9% - What's Next?

April 18, 2025 | marketbeat.com

What is William Blair's Forecast for OCUL Q1 Earnings?

April 13, 2025 | marketbeat.com

Vanguard Group Inc. Purchases 99,730 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

April 13, 2025 | marketbeat.com

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 11, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CKPT, GPCR, OCUL, and DYN Company Descriptions

Checkpoint Therapeutics NASDAQ:CKPT

$4.12 0.00 (0.00%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$4.12 0.00 (0.00%)

As of 05/2/2025 04:05 PM Eastern

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Dyne Therapeutics NASDAQ:DYN

$11.86 -0.13 (-1.08%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$12.04 +0.18 (+1.48%)

As of 05/2/2025 06:57 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Structure Therapeutics NASDAQ:GPCR

$27.09 -0.24 (-0.88%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$27.74 +0.66 (+2.42%)

As of 05/2/2025 07:54 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Ocular Therapeutix NASDAQ:OCUL

$8.80 +0.27 (+3.17%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$8.68 -0.12 (-1.31%)

As of 05/2/2025 07:14 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time